Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553470 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05553470 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT05553470, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steatohepatitis (NASH).
Interventions
- DRUG Miricorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553470
The ClinicalTrials.gov registry entry for NCT05553470 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Miricorilant is the first listed.
NCT05553470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05553470 about?
NCT05553470 is a clinical study titled "Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant". The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steato...
What is the current status of trial NCT05553470?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-03-03. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT05553470?
The interventions under investigation include: Miricorilant (DRUG).
Who is sponsoring clinical trial NCT05553470?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.